Evommune, Inc. Deferred Offering Costs
Evommune, Inc. (EVMN) had Deferred Offering Costs of $2.10 million as of 2025-09-30, per its 10-Q filed 2025-12-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2025-12-11
- 2025-09-30: Deferred Offering Costs $2.10M.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-09-30 | $2.10M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |